Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. (6th December 2018)

• Record Type: Journal Article
• Authors: Bousman, Chad A; Arandjelovic, Katarina; Mancuso, Serafino G; Eyre, Harris A; Dunlop, Boadie W
• Is Part Of: Pharmacogenomics. Volume 20:Number 1(2019)
• Page Start: 37
• Page End: 47
• Publication Date: 2018-12-06
• Subjects: antidepressants -- clinical decision support -- depression -- genetic -- pharmacogenetics; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2018-0142
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD).Patients & methods: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria.Results & conclusion: A total of 1737 eligible subjects from five RCTs were examined. Individuals receiving pharmacogenetic-guided DST therapy (n = 887) were 1.71 (95% CI: 1.17–2.48; p = 0.005) times more likely to achieve symptom remission relative to individuals who received treatment as usual (n = 850). Pharmacogenetic-guided DSTs might improve symptom remission among those with MDD.